Global AI-based Clinical Trials Solution Provider Market Size study, By Clinical Trial Phase (Phase-I, Phase-II, Phase-III), By Application (Oncology, Cardiovascular Diseases, Neurological Diseases or Conditions, Infectious Diseases, Others), By End-use (

Global AI-based Clinical Trials Solution Provider Market Size study, By Clinical Trial Phase (Phase-I, Phase-II, Phase-III), By Application (Oncology, Cardiovascular Diseases, Neurological Diseases or Conditions, Infectious Diseases, Others), By End-use (Pharmaceutical Companies, Academia, Others), and Regional Forecasts 2022-2028

Global AI-based Clinical Trials Solution Provider Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. The emergence of artificial intelligence (AI) in the research and development activities in clinical trials aids in improving operational competence, minimizing costs, and boosting drug discovery. AI technology integrated with big data helps in solving various key clinical trial challenges, which is leading the market growth. Factors such as the increase in the number of clinical studies, and growing penetration of the AI-based platforms for enhancing efficiency and productivity of trials at many stages, coupled with the development of the pharmaceutical and CROs sector are impelling the growth of the global market. For instance, as per a Statista report, in 2018, the total number of registered clinical studies worldwide was recorded at 293,259 and the figure is constantly rising and reach 409,300 studies by 2022. Accordingly, the rising clinical studies are positively influencing the growth of the AI-based Clinical Trials Solution Provider market across the globe. However, the lack of AI accuracy in clinical practices and the imposition of several stringent regulations on the approval of AI-based clinical trials hinders the growth of the market over the forecast period of 2022-2028. Also, rising R&D investments in various therapeutic areas and growing awareness and diversified applications of artificial intelligence (AI) in the field of clinical trials are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global AI-based Clinical Trials Solution Provider Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the availability of favorable government policies and the rising presence of a number of AI-based start-ups. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the growing adoption of AI-based tools, rising patient pool, as well as, increasing prevalence of various diseases, would create lucrative growth prospects for the AI-based Clinical Trials Solution Provider Market across the Asia-Pacific region.

Major market players included in this report are:
Unlearn.AI, Inc.
Saama Technologies
Antidote Technologies, Inc.
Innoplexus
Mendel.ai
Median Technologies
Symphony AI
BioAge Labs, Inc.
AiCure, LLC
Halo Health Systems

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Clinical Trial Phase:
Phase-I
Phase-II
Phase-III
By Application:
Oncology
Cardiovascular Diseases
Neurological Diseases or Conditions
Infectious Diseases
Others
By End-use:
Pharmaceutical Companies
Academia
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global AI-based Clinical Trials Solution Provider Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Unlearn.AI, Inc.
Saama Technologies
Antidote Technologies, Inc.
Innoplexus
Mendel.ai
Median Technologies
Symphony AI
BioAge Labs, Inc.
AiCure, LLC
Halo Health Systems

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.